Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   Genmab, de Deense parel

BioPharma« Terug naar discussie overzicht

Genmab, de Deense parel

Volgen
145 Posts
Pagina: «« 1 2 3 4 5 6 ... 8 »» | Laatste | Omlaag ↓
  3. [verwijderd] 9 december 2006 02:29
    Synopsis

    We initiate coverage on Danish biotech company Genmab with a BUY recommendation and a 12- month price target of DKK 425. With four products in Phase III, the company has by far the most promising pipeline in cancer in the European biotech sector. Major deals are to be expected in the coming period.

  6. [verwijderd] 13 december 2006 17:42
    Dat TO bod mag van mij nog voor het einde van dit jaar komen.

    Genmab moet inderdaad even terug. De omzetten blijven hoog, doch iets minder dan tijdens de stijging. Ik had er zelf ook al aan gedacht om tussentijds even uit te stappen, maar heb het niet gedaan.

    Genmab is zwanger van goed nieuws. Zo kunnen er ieder moment (nieuwe) partners worden bekend worden gemaakt voor de diverse medicijnen in ontwikkeling.

    Ook dan kunnen we, zonder TO, rap naar de DKK 400,-

    Let wel Genmab heeft niet direct partners nodig. Het bedrijf is een van de financieel gezondste biotechbedrijven wereldwijd.

    demo
  8. [verwijderd] 19 december 2006 08:35
    Genmab heeft grote deal gesloten met Glaxon Smith K. voor 2.1bln dollar !!

    | Print |
    Glaxo signs $2.1 bln deal for Genmab's lead drug



    LONDON, Dec 19 (Reuters) - GlaxoSmithKline Plc has bought global rights to Danish biotech company Genmab's most promising new drug, a treatment for leukemia, in a deal worth up to $2.1 billion, the two firms said on Tuesday.
    The deal covers HuMax-CD20, an experimental antibody medicine in late-stage development for CD20 positive B-cell chronic lymphocytic leukemia (B-CLL) and follicular non-Hodgkin's lymphoma. It is also in Phase II trials for rheumatoid arthritis.
    ((Reporting by Ben Hirschler; email: ben.hirschler@reuters.com; Reuters Messaging: ben.hirschler.reuters.com@reuters.net; +44 20 7542 5082))
    Keywords: GLAXO GENMAB/


    Distributed by ©Reuters Limited.
    Click for Restrictions.

  9. [verwijderd] 19 december 2006 09:07
    Dat is TOPnieuws. Anderzijds lijkt het erop, dat Genmab (nog) niet verkocht gaat worden.
    Op Yahoo zie ik ook:
    GSK paying DK 454,68 per share, a 33% premium to yesterday's closing price.

    Begrijp ik nog niet.
    Koers vrijwel onveranderd... Begrijp ik ook nog niet...
    ________________________________________________________________________

    GLAXOSMITHKLINE AND GENMAB ENTER GLOBAL AGREEMENT FOR HUMAX-CD20

    London, UK & Philadelphia, USA and Copenhagen, Denmark; December 19, 2006 - GlaxoSmithKline (GSK) and Genmab A/S (CSE:GEN) today announced a worldwide agreement to co-develop and commercialize HuMax-CD20™ (ofatumumab), a fully human monoclonal antibody in late stage development for CD20 positive B-cell chronic lymphocytic leukemia (B-CLL) and follicular non-Hodgkin's lymphoma (NHL) and in Phase II for rheumatoid arthritis (RA).

    Under the terms of the agreement, Genmab will receive a license fee of DKK 582 million (approximately £ 52 million and approximately $102 million*), and GSK will invest DKK 2,033 million (approximately £ 183 million and approximately $357 million) to purchase, 4,471,202 ordinary shares of Genmab. The total potential value of this agreement, in the event of full commercial success, in cancer and various autoimmune and inflammatory diseases, could exceed DKK 12.0 billion (approximately £ 1.1 billion and approximately $2.1 billion), including the initial license fee and equity purchase, milestone payments, totaling DKK 9.0 billion (approximately £ 0.8 billion and approximately $ 1.6 billion) and expected development, commercial manufacturing and commercialization costs.

    In addition, Genmab will be entitled to receive tiered double digit royalties on global sales of HuMax-CD20.

    GSK will receive an exclusive worldwide license to HuMax-CD20 as well as any other antibodies with affinity for the CD20 antigen which Genmab may develop. GSK will also have an exclusive option to a CD20 UniBody™ to be developed in collaboration with Genmab. GSK and Genmab will co-develop HuMax-CD20. Genmab will be responsible for development costs until 2008, including costs of the two ongoing late stage oncology studies after which development costs will be shared equally between GSK and Genmab. GSK will be solely responsible for the manufacturing and commercialization of HuMax-CD20.

    Genmab will have an option to co-promote HuMax-CD20 in a targeted oncology setting in the US and in the Nordic region. Should this be undertaken, Genmab will also have the option co-promote Bexxar™ and Arranon™ in the US and Atriance™ in the relevant countries of the Nordic region.
  12. [verwijderd] 19 december 2006 10:28
    Klopt denk wel ongeveer.
    Number of shares: 39,648,355
    En GSK koopt: 4,471,202 aandelen voor DKK 2,033 million.
    Maw GSK koopt zo'n 15 % van totaal aantal aandelen, dus koers gaat dan niet gelijk naar de koers betaald door GSK.

    Dit lijkt me een goeie deal. De speculatie was DK 425 voor TO bod. Nu al @ 410, dat zal wel verder stijgen, vooral als duidelijk wordt dat deze drug op de markt komt.

    quote:

    Kiter27 schreef:

    ja ik vind het ook wel raar dat de koers niet meer gestegen is...
  13. [verwijderd] 19 december 2006 10:41
    Reuters PB:
    Glaxo signs record $2.1 bln deal for Genmab drug
    Tuesday December 19, 4:31 am ET
    By Ben Hirschler, European Pharmaceuticals Correspondent

    LONDON (Reuters) - GlaxoSmithKline Plc (London:GSK.L - News) has bought global rights to Danish biotech company Genmab's (Copenhagen:GEN.CO - News) most promising new drug, a treatment for leukemia, in a record deal worth up to $2.1 billion, the two firms said on Tuesday.

    The agreement is the biggest ever clinched by a biotech company, eclipsing a $2-billion alliance between ImClone Systems Inc. (NASDAQ:IMCL - News) and Bristol-Myers Squibb Co. (NYSE:BMY - News) that was revised down in 2002 when ImClone's drug Erbitux hit snags.

    Genmab shares surged as much as 24 percent to a new all-time high of 424 Danish crowns in early trading, valuing the business -- which has yet to make a profit -- at close to $3 billion.

    The deal is the latest in a string of product acquisitions by large pharmaceutical firms eager to tap biotech know-how to boost their drug pipelines, and the price paid reflects the fierce competition for late-stage assets.

    It covers HuMax-CD20, an experimental human antibody in late-stage development for CD20 positive B-cell chronic lymphocytic leukemia and follicular non-Hodgkin's lymphoma.

    The drug, which is also in Phase II trials for rheumatoid arthritis, is similar to MabThera/Rituxan from Roche Holding AG (ROG.VX) and Genentech Inc. (NYSE:DNA - News).

    Genmab's chief executive said she was confident HuMax-CD20, which is expected to be filed for regulatory approval by 2008, could generate well over $2 billion in annual sales.

    "I think potential sales are higher than that and when you see the deal value, you can see that they (Glaxo) believe (that) also," Lisa Drakeman told Reuters in a telephone interview.

    Some analysts have penciled in potential sales of as much as $5 billion in cancer and arthritis, she noted.

    Jyske Bank analyst Frank Andersen, who forecasts peak sales of $2.8 billion, raised his rating on Genmab shares to "buy" from "accumulate" on the deal, saying that regulatory approval for HuMax-CD20 for its three uses would put a fair value of 470 crowns on the stock.

    The Danish group had been expected to strike a deal for the product by the middle of 2007.

    Under the agreement with Glaxo it will receive a license fee of 582 million Danish crowns ($102 million) and Glaxo will invest approximately $357 million to buy shares in Genmab.

    Genmab is also entitled to milestone payments of up to $1.6 billion, based on the drug's successful development and commercialization and will receive tiered double-digit percentage royalties on global sales of the medicine.

    GLAXO'S ANTIBODY DRIVE

    The deal is the second struck by Glaxo in the fast-growing antibody arena in less than two weeks, following its agreement to buy early-stage drug firm Domantis for 230 million pounds ($449 million) on December 8.

    Europe's biggest drugmaker has been under-represented in biological medicines, such as antibodies, in the past.

    In addition to winning rights to a promising new drug that could join its growing cancer portfolio in the near future, the tie-up with Genmab also increases Glaxo's presence in next-generation antibody technology, since it will have an exclusive option to CD20 UniBody.

    Unibody is a new antibody technology developed by Genmab offering a smaller format, which means it may work more effectively than existing monoclonal antibodies. This dovetails with Domantis's similar ultra-small antibody technology.

    Genmab is to maintain a key role in the future of HuMax-CD20 in an arrangement that underlines the strong negotiating hand of successful biotech companies.

    It will be responsible for development costs until 2008 and will have an option to co-promote HuMax-CD20 as a cancer treatment in the United States and the Nordic region.

    Genmab will also have an option to co-promote Glaxo's drugs Bexxar and Arranon in the United States and Atriance in Nordic countries.
  20. [verwijderd] 21 december 2006 18:13
    Leuk he zo'n heftig ritje. Het nieuws m.b.t. tot het aankondigen van een partner zat er al een tijdje aan te komen.

    Overname wordt hierdoor een stukje onwaarschijnlijker in mijn ogen. Wie wil er nu met een deal met de concurrentie worden geconfronteerd ??

    Ben even uitgestapt, maar kom beslist terug.

    Hopenlijk p een iets lagere koers, na winstnemingen. Maar desnoods tegen een hogere koers. Het potentieel uit dit aandeel is nog lang niet op.

    prettige feestdagen en alvast een voorspoedig beleggingsjaar.

145 Posts
Pagina: «« 1 2 3 4 5 6 ... 8 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
HEIJMANS KON 29,800 +2,20 +7,97%
AZERION 1,300 +0,05 +4,00%
AMG Critical Materials N.V. 15,200 +0,44 +2,98%
ArcelorMittal 23,990 +0,48 +2,04%
SIGNIFY NV 22,100 +0,38 +1,75%
ASR Nederland 44,940 +0,63 +1,42%
Aperam 28,220 +0,38 +1,36%
TKH 33,620 +0,42 +1,27%
Accsys 0,585 +0,01 +1,04%
Aegon 6,112 +0,06 +0,99%
PostNL 1,053 +0,01 +0,96%
ING 14,978 +0,14 +0,96%
SHELL PLC 31,055 +0,24 +0,78%
NN Group 45,300 +0,35 +0,78%
Kendrion 10,920 +0,08 +0,74%
RANDSTAD NV 41,600 +0,30 +0,73%
ACOMO 17,260 +0,12 +0,70%
RENEWI 7,430 +0,05 +0,68%
ASCX 1.209,03 +6,48 +0,54%
ALLFUNDS GROUP 5,345 +0,02 +0,47%
Flow Traders 21,200 +0,08 +0,38%
Air France-KLM 7,700 +0,02 +0,23%
Eurocommercial Properties 23,300 +0,05 +0,22%
BAM 4,170 +0,01 +0,19%
Sif Holding 12,240 +0,02 +0,16%
Wereldhave 14,100 +0,02 +0,14%
Fugro 16,130 +0,02 +0,12%
NSI 19,660 +0,02 +0,10%
DSM FIRMENICH AG 102,550 +0,05 +0,05%
UNILEVER PLC 54,400 +0,02 +0,04%
Brunel 8,590 0,00 0,00%
JDE PEET'S 18,500 0,00 0,00%
SBM Offshore 17,570 0,00 0,00%
TomTom 5,420 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
EBUSCO (RIGHT) 0,160 -0,22 -57,89%
EBUSCO HOLDING 1,266 -0,12 -8,86%
ASML 635,000 -36,60 -5,45%
Wolters Kluwer 151,650 -7,25 -4,56%
ASMI 507,600 -21,60 -4,08%
RELX 42,300 -1,48 -3,38%
Galapagos 25,540 -0,84 -3,18%
ADYEN NV 1.237,000 -39,80 -3,12%
Arcadis 62,950 -1,85 -2,85%
Pharming 0,715 -0,02 -2,79%
BESI 114,350 -2,90 -2,47%
Avantium 2,190 -0,06 -2,45%
B&S Group SA 4,300 -0,10 -2,27%
Corbion 21,840 -0,46 -2,06%
NX FILTRATION 4,540 -0,09 -2,05%
IMCD 142,150 -2,90 -2,00%
ForFarmers 3,350 -0,06 -1,90%
UMG 23,100 -0,44 -1,87%
INPOST 17,300 -0,27 -1,54%
Basic-Fit 22,820 -0,34 -1,47%
AEX 862,50 -11,98 -1,37%
THEON INTERNAT 8,980 -0,12 -1,32%
EXOR NV 93,600 -1,25 -1,32%
CM.COM 6,200 -0,08 -1,27%
Fagron 18,520 -0,20 -1,07%
Sligro 11,120 -0,12 -1,07%
JUST EAT TAKEAWAY 14,105 -0,14 -0,95%
PROSUS 37,750 -0,34 -0,88%
Heineken 71,340 -0,52 -0,72%
Ahold Delhaize 32,130 -0,22 -0,68%
FASTNED 22,050 -0,15 -0,68%
Van Lanschot Kempen NV 44,500 -0,30 -0,67%
Vastned 24,350 -0,15 -0,61%
Alfen N.V. 12,400 -0,07 -0,56%
AMX 870,21 -4,77 -0,55%
ABN AMRO BANK N.V. 14,790 -0,08 -0,54%
KPN 3,524 -0,02 -0,51%
WDP 20,620 -0,08 -0,39%
Nedap N.V. 53,400 -0,20 -0,37%
Akzo Nobel 55,680 -0,20 -0,36%
AALBERTS NV 35,220 -0,12 -0,34%
OCI 11,245 -0,03 -0,27%
Vopak 43,640 -0,10 -0,23%
Philips Koninklijke 24,560 -0,05 -0,20%
CTP 14,760 -0,02 -0,14%
vlag naam koers verschil relatief verschil
AEX 862,50 -11,98 -1,37%
AEX GR 3.382,99 -47,01 -1,37%
Germany40^ 19.239,20 -24,50 -0,13%
FTSE 100 8.063,61 -7,58 -0,09%
EURO50 4.796,06 0,00 0,00%
US30^ 43.483,80 0,00 0,00%
Nasd100^ 20.407,80 0,00 0,00%
US500^ 5.874,88 0,00 0,00%
Japan225^ 38.006,50 0,00 0,00%
VD-NEW 16,30 +0,17 +1,06%
#/^ Index indications calculated real time, zie disclaimer